Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $48.45 | Total: $242.25 |
| 1 | 10 | $41.04 | Total: $410.40 |
| 1 | 25 | $34.77 | Total: $869.25 |
| 1 | 50 | $29.64 | Total: $1,482.00 |
| 1 | 100 | $25.65 | Total: $2,565.00 |
Overview
Revumenib represents a novel therapeutic approach targeting the menin–KMT2A interaction, offering a promising treatment option for patients with specific genetic alterations in acute leukemias. Its ability to modulate gene expression and promote leukemic cell differentiation underscores its potential as a targeted therapy in hematologic malignancies.Syndax+7Nature+7ASCOPubs+7
Mechanism of Action
Revumenib functions by disrupting the binding between menin and KMT2A, which is essential for the transcriptional activation of oncogenic genes such as HOX and MEIS1. These genes are implicated in maintaining the leukemogenic state of hematopoietic stem cells. By inhibiting this interaction, revumenib leads to the downregulation of these genes, promoting differentiation and apoptosis of leukemic cells .Nature+1
Clinical Applications
Revumenib is currently under investigation in clinical trials for the treatment of relapsed or refractory acute leukemias with KMT2A rearrangements or NPM1 mutations. The AUGMENT-101 trial has demonstrated promising results, with a 47% overall response rate and a 23% complete remission rate in patients with relapsed/refractory NPM1-mutant AML. Additionally, 64% of patients achieving complete remission were minimal residual disease-negative .Nature+2Wikipedia+2Wikipedia+4Targeted Oncology+4ScienceDirect+4
Chemical Properties
| Molecular Formula | C32H47FN6O4S |
| Molecular Weight | 630.82 |
| CAS Numbers | 2169919-21-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CCN(C(C)C)C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(C1)CCN(C[C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)CC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back [relapsed] or has not gotten better with treatment [refractory].